...
首页> 外文期刊>Molecules >Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
【24h】

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib

机译:PARP抑制剂Talazoparib的光活化前药的设计,合成和体外评价

获取原文
           

摘要

In this article, we report the design, synthesis, photodynamic properties, and in vitro evaluation of photoactivatable prodrug for the poly (ADP-ribose) polymerase 1 (PARP-1) inhibitor Talazoparib. In order to yield a photoactivatable, inactive prodrug, photoactivatable protecting groups (PPGs) were employed to mask the key pharmacophore of Talazoparib. Our study confirmed the good stability and photolytic effect of prodrugs. A PARP-1 enzyme inhibition assay and PARylation experiment showed that the inhibitory activity of the prodrug was reduced 380 times and more than 658 times, respectively, which proved that the prodrug’s expected activity was lost after PPG protection. In BRCA1- and BRCA2-deficient cell lines, the inhibitory activity of the compound was significantly restored after ultraviolet (UV) irradiation. The results indicate that the photoactivatable prodrug strategy is an interesting approach for studying PARP inhibitors. Meanwhile, the described photoactivatable prodrug also provided a new biological tool for the mechanism research of PARP.
机译:在本文中,我们报告了聚(ADP-核糖)聚合酶1(PARP-1)抑制剂Talazoparib的光活化前药的设计,合成,光动力学性能和体外评价。为了产生光活化,非活性的前药,可活跃的保护基团(PPG)以掩盖Talazoparib的关键药物球体。我们的研究证实了前药的良好稳定性和光解作用。 PARP-1酶抑制测定和聚酰化实验表明,分别的前药的抑制活性分别降低了380倍和658倍,这证明了PPG保护后的预期活性损失。在BRCA1和BRCA2缺乏细胞系中,紫外(UV)照射后化合物的抑制活性明显恢复。结果表明,光活化的前药策略是研究PARP抑制剂的有趣方法。同时,所描述的光活性前药还为PARP的机制研究提供了一种新的生物工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号